Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma

M F D Baay, J M Duk, M P M Burger, J Walboomers, J ter Schegget, K H Groenier, H W A de Bruijn, E Stolz, P Herbrink

Abstract

Aims—To investigate the correlation between antibodies to the transforming protein E7 of human papillomavirus (HPV) type 16 and clinicopathological indices in women with cervical squamous carcinoma.

Methods—A synthetic peptide of the HPV type 16 E7 protein (amino acids 6 to 35) was used to screen sera from 29 children, 130 women with cervical intraepithelial neoplasia, 443 women with cervical cancer, and 222 controls, for antibodies against this viral antigen. Bivariate and multivariate analyses were used to investigate the correlation between the serological status in the pretreatment sera and clinicopathological indices (size of the lesion, histological grade, stromal infiltration, vascular invasion, and nodal spread). Survival analysis was done using the Cox regression model for all FIGO stages and stages IB and IIA.

Results—Cervical carcinoma patients had a significantly higher prevalence of antibodies to synthetic peptide E76–35 than women with cervical intraepithelial neoplasia (17.7% vs 7%, p<0.005) or controls (17.7% vs 11%, p<0.05). Bivariate analysis of the data on the presence of anti-E76–35 antibodies in the pretreatment sera from these patients and clinicopathological indices showed a significant correlation between the presence of anti-E76–35 antibodies and the size of the lesion (p = 0.0009), histological grade (p = 0.031), and lymph node metastasis (p = 0.011). In addition, the Cox regression model, analysing four risk factors which can be determined before treatment, showed a significant correlation between the presence of anti-E76–35 antibodies and a worse prognosis (p = 0.003). Survival analysis revealed that both for all FIGO stages (p = 0.0005) and for stages IB and IIA alone (p = 0.0021), anti-E76–35 positive patients before treatment had a significantly shorter life expectancy.

Conclusions—The presence of antibodies against E76–35 in pretreatment sera from patients with cervical carcinoma correlates with the size of the lesion, lymph node involvement, and a worse prognosis.

Keywords: Human papillomavirus, cervical cancer, antibody response.

Human papillomaviruses (HPV) are a group of viruses which are associated with various proliferative diseases in the infected epithelium.1 To date, more than 70 HPV types have been reported. Some of these, among which HPV types 6, 11, 16, and 18 are the most common, are associated with lesions in the anogenital tract.2 The "benign" types 6 and 11 are mainly associated with condylomata acuminata. Of the oncogenic HPV types, HPV-16 is most frequently found in cervical carcinomas and the viral genome is often found integrated into the cellular genome.3 The nuclear protein E7 of HPV-16 is considered to be one of the two major proteins involved in malignant transformation and the maintenance of the transformed phenotype of cells. The viral oncoprotein E7 is consistently transcribed in both HPV positive cervical cancer cell lines and cervical cancers.4,5

Until recently, few data were available on the humoral immune response to HPV-16. Jochmus-Kudielka et al6 have reported a 14-fold higher prevalence of antibodies to HPV-16 E7 in sera from cervical carcinoma patients than in age and sex matched controls, when fusion proteins were used in western blotting assays for the screening of sera for the presence of HPV antigen specific antibodies. Using synthetic peptides with known B cell epitopes,7–9 similar results have been obtained to those found with western blotting by Jochmus-Kudielka et al.9

To date, no data have been published concerning the prevalence of antibodies against HPV-16 E7 in sera from patients with cervical squamous cell carcinoma in relation to tumour indices, such as lesion size and nodal spread, or to survival. To investigate the possible correlation between the presence of antibodies against HPV-16 E7 and tumour indices, pretreatment sera from cervical carcinoma patients were tested in an enzyme linked immunoabsorbant assay (ELISA) using a synthetic peptide. This peptide was chosen to represent reported major B cell epitopes of HPV-16 E7
Papillomavirus antibodies and carcinoma of the cervix

Using bivariate and logistic regression analysis, the results obtained for these cervical cancer patients were correlated with the size of the lesion, histological grade, stromal infiltration, vascular invasion, and nodal spread. In addition, anti-E7 positivity was related to survival.

Methods

Sera

The age distribution of patient and control groups is shown in Table 1. Twenty-nine sera of children between 0-5 and 9 years of age were used to determine the cut off value. One hundred and thirty sera from women with different grades of cervical intraepithelial neoplasia (CIN) and 51 sera from patients with squamous cell cervical carcinoma were obtained from the Department of Gynaecology, University of Amsterdam (head: Prof Dr F B Lammas). A further 392 pretreatment sera from women with squamous cell cervical carcinoma were obtained from the Department of Obstetrics and Gynaecology, University Hospital Groningen. The control group consisted of 222 healthy women with a similar age distribution. No data on HPV DNA typing were available. All women in the Amsterdam control group had normal cytology and were matched to the cancer patient group for age, sex, and socioeconomic status. The control group for cervical cancer patients from Groningen consisted of sera sent in for routine screening for other infectious diseases. No data on cytology were available from the Groningen control group.

Clinicalopathological indices in patients with cervical carcinoma

The staging of the 443 patients with cervical carcinoma was according to the recommendations of the International Federation of Gynecology and Obstetrics (FIGO). Clinicalopathological data other than stage were only available from 300 patients treated in Groningen. Patients from whom blood samples had been drawn after exconisation were excluded from the analysis. Examination of the patients was performed under general anaesthesia. During this procedure, the lesion size (largest diameter) was estimated routinely and expressed in centimetres for the large majority of patients.

Table 1 Age distribution of patient and control groups

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Mean age (SD) (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children</td>
<td>29</td>
<td>3-6 (2-5)</td>
</tr>
<tr>
<td>CIN 1-3</td>
<td>130</td>
<td>32-5 (7-9)</td>
</tr>
<tr>
<td>SCC</td>
<td>443</td>
<td>50-9 (15-7)</td>
</tr>
<tr>
<td>SCC Amsterdam</td>
<td>51</td>
<td>52-5 (13-0)</td>
</tr>
<tr>
<td>SCC Groningen</td>
<td>392</td>
<td>50-7 (16-0)</td>
</tr>
<tr>
<td>All controls</td>
<td>222</td>
<td>50-2 (16-3)</td>
</tr>
<tr>
<td>Controls Amsterdam</td>
<td>59</td>
<td>51-2 (12-8)</td>
</tr>
<tr>
<td>Controls Groningen</td>
<td>165</td>
<td>49-3 (17-7)</td>
</tr>
</tbody>
</table>

CIN = cervical intraepithelial neoplasia; SCC = squamous cell carcinoma.

Patients with stage IB or IIA were mainly treated by preoperative intracavitary radiotherapy, followed by radical hysterectomy with bilateral paraaortic lymphadenectomy and pelvic lymphadenectomy four weeks later. Postoperative whole pelvis radiotherapy was applied if lymph node metastases or positive resection margins, or both, were present. Patients with stage IIB and most of the patients with stage III were treated by radiotherapy only, if possible followed by adjunctive hysterectomy. In the remaining stage III patients and in all stage IV patients, treatment was individualised using combinations of radiotherapy, surgery, and chemotherapy.

To correlate anti-E7 positivity with the histopathological data in bivariate analysis, all the available biopsy or cone material of 300 patients was carefully reviewed. Tumours were classified into well differentiated (grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3), or undifferentiated (grade 4) squamous cell carcinoma, in accordance with the criteria laid down by Ferenczy and Winkler.

Criteria for the assessment of the clinical course of the disease were described previously. Briefly, "complete remission" (no evidence of disease) was defined as the absence of all tumour lesions three months after completion of treatment or during follow up. "Residual disease" existed when tumour lesions were still known to be present after treatment. "Progression of disease" was defined as the appearance of new lesions, the growth of a pelvic mass or other known tumour lesions, or a distinct deterioration in the clinical status of a patient with a known tumour ultimately resulting in death. "Recurrent disease" was used to indicate the reappearance of disease in patients who experienced complete remission. "Poor prognosis" is used to indicate the risk for residual, progressive, or recurrent disease. From 367 patients with cervical carcinoma, consecutively admitted and treated at the Department of Gynaecological Oncology in Groningen, follow up data were available. Of these 367 patients, 106 died of cancer.

Synthetic peptide

The synthetic peptide, encompassing amino acids 6-35 (PTLHEYMLDLQETTDLY-CYEQLNDSSEE) of the HPV-16 E7 ORF, was purchased from the Department of Immunology and Medical Microbiology, TNO Medical Biological Laboratory, Rijswijk, The Netherlands. The peptide was synthesised by solid phase synthesis according to Merrifield on polystyrene resin (1% cross linking), using an automated peptide synthesiser (SAM-2, Biosearch). Synthetic peptides were purified by chromatography on Sephadex G-15 and reverse phase high performance liquid chromatography (HPLC).

ELISA

Synthetic peptide (100 μl per well at 5 μg/ml in phosphate buffered saline (PBS), pH 7-2)
was coated onto 96-well Maxisorp plates (Nunc) for one hour at 37°C. Control wells were treated in a similar way, with the omission of synthetic peptide from the buffer. After six rinses with distilled water the plates were blocked with 1% gelatin in PBST (PBS containing 0-05% Tween 20) for one hour at 37°C. Sera were incubated in a 1:100 dilution in PBST + 1% gelatin for one hour at 37°C. Goat anti-human IgG peroxidase (1:6700 in PBST, 1% gelatin, Diagnostic Centre SSDZ) was used as a conjugate. After one hour at 37°C the plates were washed six times (PBST), after which substrate was added (3,3', 5,5'-tetramethyl-bendizine, Aldrich Chemie). After 20 min the reaction was stopped with 2N H2SO4 and colour development read with a Titertek Plate reader at 450 nm.

Each sample was tested in at least three independent experiments. Sera which were eventually scored as equivocal were tested in at least five independent experiments. In each experiment all sera were tested in duplicate on peptide coated wells and control wells, and the mean reactivity of the control wells was subtracted from the mean reactivity of the coated well. A cut off value was determined from the children’s sera using the mean absorption + 3 times the standard deviation as described by Krchnak et al.1 For intratest comparison, positive, negative, and borderline positive sera were included in each plate. For intertest comparison, optical densities were recalculated into ratios by division by the cut off value. Using the cut off values, none of the children’s sera was found positive for antibodies against synthetic peptide E7\6-35.

### STATISTICAL METHODS

The relationship between clinical stage of the tumour and the presence of anti-HPV-16 E7 antibodies was calculated using the Pearson χ² test to compare the frequency of the presence of antibodies between 2 or >2 groups. The interrelationships between anti-E7\6-35 positivity in pretreatment sera from cervical carcinoma patients and tumour related variables were investigated using bivariate and logistic regression analysis. The prognostic value of anti-E7\6-35 and other possible risk factors was determined in the Cox regression model. The data used for bivariate and logistic regression analysis of the Groningen patient group included stage of disease (FIGO stage), lesion size, tumour grade, lymph node status, vascular invasion, depth of infiltration, and presence of antibodies against E7 synthetic peptide 6-35. Differences between survival curves were computed by means of the log rank test.

### Results

#### PREVALENCE OF ANTI-E7\6-35 ANTIBODIES IN PATIENT GROUPS AND CONTROLS

The seroreactivity of the different groups to synthetic peptide E7\6-35 is shown in table 2. Twenty four sera, 19 from patients with cervical carcinoma, one from a CIN patient, and four from controls matched to the cervical carcinoma patients, did not give consistent results on repeated testing. These sera, which gave both low positive and high negative results, were scored as equivocal and excluded from statistical analyses.

With peptide E7\6-35, seroreactivity was significantly higher in patients with invasive carcinoma than in the group of matched controls (p<0-05), or women with CIN (p<0-005). No significant differences were found for seroreactivity against peptide E7\6-35 between patients with different grades of CIN (CIN 1–3; data not shown).

### PREVALENCE OF ANTI-E7\6-35 ANTIBODIES IN DIFFERENT FIGO STAGES

Prevalence rates of antibodies against peptide E7\6-35 in the different FIGO stages of patients with invasive carcinoma are shown in table 3. When seroreactivity against peptide E7\6-35 was compared between the four FIGO stages, a statistically significant trend of increasing seropositivity with increasing stage was obtained ($\chi^2 = 6·38; \text{df}=1; \text{p}=0·01$). Analysis

### Table 3  Prevalence of antibodies against HPV-16 E7\6-35 in sera from 424 patients according to the stage of disease

<table>
<thead>
<tr>
<th>FIGO stage</th>
<th>N</th>
<th>Anti-E7\6-35 positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>203</td>
<td>30 (4-6)</td>
</tr>
<tr>
<td>II</td>
<td>163</td>
<td>30 (18-4)</td>
</tr>
<tr>
<td>III</td>
<td>39</td>
<td>5 (12-8)</td>
</tr>
<tr>
<td>IV</td>
<td>19</td>
<td>10 (52-6)</td>
</tr>
</tbody>
</table>

### Table 2  Prevalence of antibodies against HPV-16 E7\6-35 in sera from patients with cervical intraepithelial neoplasia (CIN), cervical cancer, and controls

<table>
<thead>
<tr>
<th></th>
<th>Anti-E7\6-35 positive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>CIN</td>
<td>129</td>
</tr>
<tr>
<td>Cervical carcinoma</td>
<td>424</td>
</tr>
<tr>
<td>Controls</td>
<td>218</td>
</tr>
</tbody>
</table>

* p<0-05, † p<0-005 v cervical carcinoma patients.
Papillomavirus antibodies and carcinoma of the cervix

Correlation of Anti-E7\textsuperscript{6-35} in Pretreatment Sera from Patients with Cervical Carcinoma with Clinico-pathological Indices

We examined whether tumour associated factors are related to the E7\textsuperscript{6-35} serum levels. The results are shown in Table 4. Before treatment patients with a lesion size ≥ 4 cm had a significantly higher prevalence of antibodies against E7\textsuperscript{6-35} than patients with a lesion size < 4 cm (p = 0.0009). In addition, patients with poorly or undifferentiated carcinoma or with lymph node metastases showed a significantly higher prevalence rate of antibodies against E7\textsuperscript{6-35} compared to patients with well or moderately differentiated squamous cell carcinoma (p = 0.031) or without lymph node metastases (p = 0.011). Finally, for patients with vascular invasion of the tumour a significantly higher prevalence rate of anti-E7\textsuperscript{6-35} was found in comparison with patients without vascular invasion (p = 0.04). In the analysis of clinico-pathological data on anti-E7\textsuperscript{6-35} using logistic regression analysis we considered stage, lesion size, differentiation grade, and presence or absence of lymph node metastases. The analysis revealed a significant independent effect of both a lesion size ≥ 4 cm and nodal spread on anti-E7\textsuperscript{6-35} positivity ($\chi^2 = 17.64; df = 2; p = 0.0001$; sensitivity 33-3%; specificity 90-2%).

We further analysed the predictive value of four pretreatment indices (stage, lesion size, differentiation grade, and anti-E7\textsuperscript{6-35} positivity) for the presence of lymph node metastases. Logistic regression analysis showed a statistically significant effect of both anti-E7\textsuperscript{6-35} positivity and lesion size before treatment on nodal spread ($\chi^2 = 13.01; df = 2; p = 0.0015$; sensitivity 28-2%; specificity 90-5%).

Anti-E7\textsuperscript{6-35} Antibodies and Prognosis

When the presence of antibodies against E7\textsuperscript{6-35} in pretreatment sera was correlated with prognosis, a significantly higher prevalence rate of antibodies against E7\textsuperscript{6-35} was found in patients who ultimately died of disease (32/105, 30-5%) in comparison with patients who showed no evidence of disease at the closing date of the study (35/243, 14-4%; p = 0.0008).

We performed an analysis of data of 144 patients with stage IB or IIA. Using the Cox regression model we considered three pre-treatment prognostic factors (age, lesion size, and histological grade), which can be determined before surgery, and E7\textsuperscript{6-35} positivity (since the lymph node status cannot be determined before surgery, these data were not included). The analysis revealed independent effects of anti-E7\textsuperscript{6-35} positivity (p = 0.01) and—to a lesser extent—lesion size (p = 0.07) on survival. Survival curves in relation to anti-E7\textsuperscript{6-35} positivity are shown in the figure. Statistical analysis of the survival curves (log rank test) showed that seropositive stage IB and IIA patients have a significantly shorter life expectancy than seronegative patients (p = 0.0021). A similar difference in survival was found for all stages taken together (p = 0.0005).

Discussion

Up to now, no data have been available on the correlation between antibodies against HPV-16 E7 in pretreatment sera from patients with cervical carcinoma and tumour or patient related variables.

An overall prevalence rate of antibodies against peptide E7\textsuperscript{6-35} of 17-7% was found in patients with cervical cancer, which was significantly higher than in the control group or in patients with cervical intraepithelial neoplasia. Similar results have been reported earlier. Jochmus-Kudielka et al.\textsuperscript{*} using a bacterial HPV-16 E7 fusion protein, reported a prevalence rate of 20-5% in cervical cancer patients. Krchnak et al.\textsuperscript{19} using a synthetic peptide comprising amino acids 11 to 30, obtained a prevalence rate of 24%. Müller et al.\textsuperscript{18} using a peptide identical to peptide E7\textsuperscript{6-35} in this study, found a prevalence rate of 37% in HPV-16 DNA positive cervical cancer patients. Unfortunately, no data concerning the presence of HPV DNA in the tumour tissues were available from the cervical cancer patients in this study.

When cervical cancer patients were classified according to stage, a significantly different prevalence rate of antibodies against E7\textsuperscript{6-35} was observed between the four FIGO stages, the highest prevalence being observed in stage IV patients. Further analysis of the data on anti-E7 positivity in relation to clinico-pathological indices revealed a significant correlation between the presence of antibodies against HPV-16 E7\textsuperscript{6-35} in pretreatment sera and a larger lesion size, dedifferentiation, and lymph node status...
metastasis. After logistic regression analysis only lesion size and the node status showed an independent effect on anti-E7 positivity. This latter finding is in agreement with the data from Onda et al., which show that lymph node and distant metastases are more frequent in antibody positive patients than in antibody negative patients.

Anti-E7 positivity was also shown to provide prognostic information. When the prognostic value of anti-E7 positivity was analysed in addition to three prognostic indices which can be determined before therapy (age, lesion size, and histological grade), only anti-E7 positivity correlated with poor survival. The prognostic value of pretreatment anti-E7 positivity may be explained by the association of anti-E7 positivity and tumour spread to the regional lymph nodes, which is a strong indicator of poor prognosis.

In conclusion, the results of this study show that the presence of antibodies against E7/6–35 in pretreatment sera from patients with cervical carcinoma correlates with the size of the lesion, lymph node involvement, and a worse prognosis. However, since anti-E7/6–35 antibodies are only detected in a minority of patients with cervical cancer, the clinical value of detection of antibodies against E7/6–35 as a tumour or progression marker is low. The use of E7 antigens resembling the native state, possibly in combination with E6 antigens, might lead to assays with greater sensitivity and specificity. 11,18,19 The results obtained in this study warrant further studies on the value of antibodies against E7 as tumour or progression markers using E7 antigens resembling the native state.

The authors gratefully acknowledge the excellent technical assistance of Barbara Kremer, Andrew Beever, and Colette Vermeulen. We would also like to thank Klasse ten Hoor and Mindert Kraus for collection of serum samples and data management. This study was partly financed by the Dutch Prevention Fund, grant No. 1502.

Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma.

M F Baay, J M Duk, M P Burger, J Walboomers, J ter Schegget, K H Groenier, H W de Bruijn, E Stolz and P Herbrink

doi: 10.1136/jcp.48.5.410

Updated information and services can be found at:
http://jcp.bmj.com/content/48/5/410

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/